Epigenetic Reprogramming in Relapse/Refractory AML
Palo Alto (17 mi)Age: < 65
Sex: Any
Travel: May be covered
Time Reimbursement: Varies
Trial Phase: Phase 1
Waitlist Available
Sponsor: Therapeutic Advances in Childhood Leukemia Consortium
No Placebo Group
Trial Summary
What is the purpose of this trial?This is a pilot study using decitabine and vorinostat before and during chemotherapy with fludarabine, cytarabine and G-CSF (FLAG).
Eligibility Criteria
Treatment Details
1Treatment groups
Experimental Treatment
Group I: OtherExperimental Treatment5 Interventions
decitabine, vorinostat, fludarabine, high dose cytarabine, filgrastim (G-CSF)
Cytarabine is already approved in United States, European Union, Canada for the following indications:
🇺🇸 Approved in United States as Cytosar-U for:
- Acute myeloid leukemia
- Acute lymphocytic leukemia
- Chronic myeloid leukemia
- Meningeal leukemia
🇪🇺 Approved in European Union as Depocyt for:
- Lymphomatous meningitis
🇨🇦 Approved in Canada as Cytosar-U for:
- Acute myeloid leukemia
- Acute lymphocytic leukemia
- Chronic myeloid leukemia
Find a clinic near you
Research locations nearbySelect from list below to view details:
Sainte Justine University HospitalMontreal, Canada
Children's Hospital of PhiladelphiaPhiladelphia, PA
Cook Children's Medical CenterFort Worth, TX
Primary Children's HospitalSalt Lake City, UT
More Trial Locations
Loading ...
Who is running the clinical trial?
Therapeutic Advances in Childhood Leukemia ConsortiumLead Sponsor